| EPE1009 | The effect of Covid-19 on HIV services at HIV-care clinics in Myanmar | E-poster | Impact of COVID-19 on HIV prevention, testing and treatment (including financing) |
| OAC0303 | The effect of primary health care on AIDS: a cohort study of 3.4 million individuals in Brazil | Oral abstract session with live Q&A | HIV prevention research |
| MOPEE07 | The effect of receiving an oral PrEP delivery model supported with a preferred HIV testing modality on PrEP continuation outcomes: findings from a randomized implementation trial in Kenya | Poster exhibition | Implementation science and scale up of HIV testing |
| EPE0823 | The effect of the Universal Test and Treat policy uptake on CD4 count testing and incidence of opportunistic infections in Cameroon: retrospective analysis of routine data | E-poster | Implementation science and scale up of treatment |
| OAC0104 | The effect of unplanned care interruptions on the mortality of adults resuming antiretroviral therapy in South Africa: a survival analysis | Oral abstract session with live Q&A | Epidemiology of HIV |
| TUPED03 | The effects of childhood trauma and mental health symptoms on adherence among youth living with HIV in Botswana | Poster exhibition | Key populations and other vulnerable populations: Behavioural, social and cultural issues and contexts |
| TUPEA02 | The effects of HIV-1 antigen expanded specific T cell therapy (HXTC) and vorinostat on persistent HIV-1 in people living with HIV on antiretroviral therapy | Poster exhibition | Understanding and targeting persistent HIV reservoirs |
| EPC0429 | The effects of MyChoices and LYNX mobile applications on HIV testing and PrEP use by young U.S. sexual minority men | E-poster | Population-specific interventions for HIV prevention |
| EPB0145 | The epidemiological profile of mpox cases in Rio de Janeiro, Brazil: changes over time during the 2022 outbreak | E-poster | Co-infections (including opportunistic infections) |
| OAA0204 | The EZH2 inhibitor Tazemetostat increases MHC-I antigen presentation in vitro and in vivo, enhancing antiviral activities of HIV-specific CTLs | Oral abstract session with live Q&A | Novel treatment and prevention strategies |